We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
EMPAVELI (Apellis Australia Pty Ltd)
Product name
EMPAVELI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
243 (255 working days)
Active ingredients
pegcetacoplan
Registration type
NCE/NBE
Indication
EMPAVELI (solution for injection) is indicated for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have an inadequate response to, or are intolerant of, a C5 inhibitor.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.